DOX Stock Analysis: Amdocs | NASDAQ
Software - Infrastructure | NASDAQ, USA | Market Cap: 5.996m USD | 12M Return: -27.7% | GB0022569080 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.6M
EPS Trend: 98.0%
Qual. Beats: 1
Rev. Trend: -84.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amdocs Limited (NASDAQ: DOX) is a software and services provider serving communications, entertainment, and media service providers globally. The company offers a broad portfolio spanning customer experience, monetization, intelligent networking, charging, eSIM, and digital marketplace solutions, with its CES25 suite serving as a telco-native, GenAI-led platform that integrates AI agents across business, operations, and network domains. Its offerings include the Customer Engagement Platform (a telecom-specific CRM), Amdocs Monetization Suite, Amdocs Intelligent Networking Suite, Amdocs Charging, Amdocs eSIM Cloud, MarketONE (a SaaS-based digital services marketplace), connectX (a cloud-native telco-in-a-box platform), and CatalogONE (which embeds business intelligence with telecom-specific GenAI agents). Beyond software, Amdocs provides consulting, systems integration, managed services, network deployment and optimization, and professional services, including capabilities in predictive analytics and robotic process automation. Founded in 1982 and headquartered in Saint Louis, Missouri, the company has been publicly traded since its 1998 IPO.
Amdocs operates in the business support systems/operations support systems (BSS/OSS) segment of the IT services market, a specialized niche focused on helping telecommunications carriers run billing, customer management, and network operations. Its classification within the GICS Information Technology sector, under the IT Consulting & Other Services sub-industry, reflects its hybrid model that combines proprietary software products with recurring managed services revenue.
- CES25 GenAI suite adoption drives managed services revenue growth
- Strong dollar pressures margins on international revenue exposure
- Competition from Accenture and Infosys pressures deal pricing
| Net Income: 454.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.13 > 1.0 |
| NWC/Revenue: -2.36% < 20% (prev 6.47%; Δ -8.83% < -1%) |
| CFO/TA 0.12 > 3% & CFO 748.8m > Net Income 454.7m |
| Net Debt (1.04b) to EBITDA (847.2m): 1.23 < 3 |
| Current Ratio: 0.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.7m) vs 12m ago -4.94% < -2% |
| Gross Margin: 37.81% > 18% (prev 37.24%; Δ 0.58% > 0.5%) |
| Asset Turnover: 73.00% > 50% (prev 73.38%; Δ -0.38% > 0%) |
| Interest Coverage Ratio: 14.78 > 6 (EBIT TTM 638.0m / Interest Expense TTM 43.2m) |
| A: -0.02 (Total Current Assets 1.59b - Total Current Liabilities 1.70b) / Total Assets 6.42b |
| B: 1.14 (Retained Earnings 7.35b / Total Assets 6.42b) |
| C: 0.10 (EBIT TTM 638.0m / Avg Total Assets 6.37b) |
| D: 1.06 (Book Value of Equity 3.29b / Total Liabilities 3.09b) |
| Altman-Z'' = 5.41 = AAA |
| DSRI: 1.05 (Receivables 1.01b/956.6m, Revenue 4.65b/4.65b) |
| GMI: 0.98 (GM 37.24% / 37.81%) |
| AQI: 1.04 (AQ_t 0.61 / AQ_t-1 0.59) |
| SGI: 1.00 (Revenue 4.65b / 4.65b) |
| TATA: -0.05 (NI 454.7m - CFO 748.8m) / TA 6.42b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of October 01, 2026, the stock is trading at USD 57.18 with a total of 1,677,796 shares traded. Over the past week, the price has changed by -1.04%, over one month by -8.42%, over three months by +14.27% and over the past year by -27.73%.
Current recommended Stop Loss: 55.20 (which is 3.5% or 1.4 ATR below the current price).
Amdocs has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy DOX.
- StrongBuy: 3
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 79.3 | 38.6% |
P/E Trailing = 13.639
P/E Forward = 7.0922
P/S = 1.2885
P/B = 1.8683
P/EG = 0.7882
Revenue TTM = 4.65b USD
EBIT TTM = 638.0m USD
EBITDA TTM = 847.2m USD
Long Term Debt = 647.4m USD (from longTermDebt, last quarter)
Short Term Debt = 314.7m USD (from shortTermDebt, last quarter)
Debt = 1.25b USD (from shortLongTermDebtTotal, last quarter) + Leases 159.6m
Net Debt = 1.04b USD (calculated: Debt 1.25b - CCE 206.5m)
Enterprise Value = 7.04b USD (6.00b + Debt 1.25b - CCE 206.5m)
Interest Coverage Ratio = 14.78 (Ebit TTM 638.0m / Interest Expense TTM 43.2m)
EV/FCF = 11.01x (Enterprise Value 7.04b / FCF TTM 638.8m)
FCF Yield = 9.08% (FCF TTM 638.8m / Enterprise Value 7.04b)
FCF Margin = 13.73% (FCF TTM 638.8m / Revenue TTM 4.65b)
Net Margin = 9.77% (Net Income TTM 454.7m / Revenue TTM 4.65b)
Gross Margin = 37.81% ((Revenue TTM 4.65b - Cost of Revenue TTM 2.89b) / Revenue TTM)
Gross Margin QoQ = 39.76% (prev 37.04%)
Tobins Q-Ratio = 1.10 (Enterprise Value 7.04b / Total Assets 6.42b)
Interest Expense / Debt = 3.46% (Interest Expense 43.2m / Debt 1.25b)
Taxrate = 21.59% (126.0m / 583.5m)
NOPAT = 500.2m (EBIT 638.0m * (1 - 21.59%))
Current Ratio = 0.94 (Total Current Assets 1.59b / Total Current Liabilities 1.70b)
Debt / Equity = 0.38 (Debt 1.25b / totalStockholderEquity, last quarter 3.29b)
Debt / EBITDA = 1.23 (Net Debt 1.04b / EBITDA 847.2m)
Debt / FCF = 1.63 (Net Debt 1.04b / FCF TTM 638.8m)
Total Stockholder Equity = 3.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.13% (Net Income 454.7m / Total Assets 6.42b)
RoE = 13.45% (Net Income TTM 454.7m / Total Stockholder Equity 3.38b)
RoCE = 15.84% (EBIT 638.0m / Capital Employed (Equity 3.38b + L.T.Debt 647.4m))
RoIC = 10.37% (NOPAT 500.2m / Invested Capital 4.82b)
WACC = 6.35% (E(6.00b)/V(7.24b) * Re(7.11%) + D(1.25b)/V(7.24b) * Rd(3.46%) * (1-Tc(0.22)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.59 | Cagr: -4.46%
[DCF] Terminal Value 75.44% ; FCFF base≈638.8m ; Y1≈641.6m ; Y5≈680.0m
[DCF] Fair Price = 91.32 (EV 10.6b - Net Debt 1.04b = Equity 9.54b / Shares 104.4m; r=8.35% [WACC [floored]]; 5y FCF grow 0.03% → 2.50% )
EPS Correlation: 98.01 | EPS CAGR: 7.99% | SUE: 1.15 | # QB: 1
Revenue Correlation: -84.27 | Revenue CAGR: -3.36% | SUE: 0.27 | # QB: 0
EPS current Quarter (2026-12-31): EPS=1.93 | Chg30d=-1.28% | Revisions=-40% | Analysts=4
EPS current Year (2026-09-30): EPS=7.42 | Chg30d=+0.18% | Revisions=+12% | GrowthEPS=+6.2% | GrowthRev=+3.7%
EPS next Year (2027-09-30): EPS=8.03 | Chg30d=-0.35% | Revisions=+29% | GrowthEPS=+8.2% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: +7% (up=6, down=5)